Efficiency of Cocarnit preparation in clinical course of alcohol dependence at withdrawal syndrome stage

2017 ◽  
Vol 41 (S1) ◽  
pp. S395-S396
Author(s):  
I. Sosin ◽  
O. Goncharova ◽  
Y. Chuev
Keyword(s):  
Alcohol Dependence ◽  
Withdrawal Syndrome ◽  
Clinical Laboratory ◽  
Clinical Course ◽  
Alcohol Withdrawal Syndrome ◽  
Clinical Score ◽  
Integrated Treatment ◽  
Sf 36 ◽  
Competing Interest ◽  
Scientific Attention

IntroductionRecently scientific attention of Ukrainian narcology was focused on the group of new complex pharmacological preparations with polymodal pathogenic effect option (Cocarnit, World Medicine, Great Britain).Aims and objectivesTo ground feasibility of Cocarnit application in complex treatment of alcohol withdrawal syndrome (AWS).MethodEleven patients with alcohol addiction were examined. An integrated research of relieving and adjuvant effects of pharmacological preparation Cocarnit in complex with traditional detoxication therapy in clinical course of alcohol dependence at AWS stage was carried out. One to 2 ampoules of Cocarnit were injected intramuscularly once per 24 hrs, № 6.MethodsClinical-psychopathological, clinical-laboratory, consulting of specialists, methods of psychological investigation (CIWA; САН; SF-36) at day 1, 7 and 14 of treatment.ResultsAWS quantification score on admission was 41. Further therapeutic regress of all AWS components was registered. At day 1 the patient's condition started improving, clinical score was 32; at day 3 – 17; day 5 – the score was 13, insignificant tremor remained. At day 7 of treatment, practically complete relieving effect of the therapy was ascertained. With САН method at day 7 of the treatment, an increase of figures in all scales was registered: state of health 2.7, activity 2.4, mood 2.5. SF-36 method: at day 1 – the score was 24, day 7 – 32, day 14 – 49.ConclusionsThus, the developed by us method of integrated treatment with inclusion of Cocarnit for withdrawal state in alcohol addicts allows to stop acute signs of pathology within 3–5 days.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Intraoperative Alcohol Withdrawal Syndrome: A Coincidence or Precipitation?

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Asish Subedi ◽  
Balkrishna Bhattarai
Keyword(s):  
Alcohol Dependence ◽  
Spinal Anesthesia ◽  
Local Anesthetic ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Spinal Block ◽  
Local Anesthetic Toxicity ◽  
Neck Fracture ◽  
Intraoperative Period

As the prevalence of alcohol dependence is approximately half in surgical patients with an alcohol use disorder, anesthetist often encounters such patients in the perioperative settings. Alcohol withdrawal syndrome (AWS) is one of the most feared complications of alcohol dependence and can be fatal if not managed actively. A 61-year-old man, alcoholic with 50 h of abstinence before surgery, received spinal anesthesia for surgery for femoral neck fracture. To facilitate positioning for spinal anesthesia, fascia iliaca compartmental block with 0.25% bupivacaine (30 mL) was administered 30 min prior to spinal block. Later, in the intraoperative period the patient developed AWS; however, the features were similar to that of local anesthetic toxicity. The case was successfully managed with intravenous midazolam, esmolol, and propofol infusion. Due to similarity of clinical features of AWS and mild local anesthetic toxicity, an anesthetist should be in a position to differentiate the condition promptly and manage it aggressively.

Psychosomatic and psychopathological paradigms of alcoholic anorexia

2017 ◽  
Vol 41 (S1) ◽  
pp. S313-S314
Author(s):  
I. Sosin ◽  
Y. Chuev ◽  
O. Goncharova ◽  
G. Misko ◽  
A. Volkov
Keyword(s):  
Anorexia Nervosa ◽  
Secondary Prevention ◽  
Intestinal Obstruction ◽  
Food Consumption ◽  
Alcohol Withdrawal ◽  
Clinical Course ◽  
Alcohol Withdrawal Syndrome ◽  
Early Stages ◽  
Syndrome Diagnosis ◽  
Competing Interest

IntroductionAlcoholic anorexia (AA), being one of prevalent narcology diseases, up to now has not been studied in psychosomatics and psychopathology paradigm.Aims and objectivesTo identify multifactorial pathopsychological, psychopathological, nervous, alimentary, toxicological constituents of AA pathogenesis.MethodTwenty-four patients with alcohol dependence (males aged 29–37) have been studied. Diagnosis was objectified by psychosomatic, pathopsychological complex international valid tests and rating, adequate for investigation design, laboratory, electrophysiology, biochemical, ultrasound and other methods.ResultsAA was accompanied with mental and physical post-intoxication exhaustion, asthenizing, tremor, dissomnia, depression, pre-delirium signs. Psychosomatic concept was proposed for reasonable identification of intranosological AA clinical forms in narcological clinical course. Anorectic dipsomaniac conditions are explained pathogenetically with psychosomatic mechanisms of deviant addictive craving behaviour as pathopsychological target and patient's intentional complete or partial refuse food consumption in favour of real in time more quick and brutal attainment of alcoholic drunkenness (Ebrietas Alcogolica). This anorexia fabula draws AA closer to Anorexia Nervosa and mostly reflects compulsive obsession with alcohol use. Pathopsychological, psychosomatic, neurogenous mechanisms of alcoholic anorexia of drinking bout early stages are transformed gradually to post-intoxication alimentary, nervous, psychic exhaustion. Meanwhile, АА is valid for alcohol withdrawal syndrome diagnosis and plays situation relapsing role in alcoholizing prolongation.ConclusionsAlcoholic anorexia is starting to declare even at early stages of alcoholic addiction formation. It is more illustrative in periodically recurrent and exaggerating drinking bouts when dynamic intestinal obstruction risk is high. Findings obtained ground alcoholic anorexia attribution to urgent conditions with necessary integrated relieving therapy and secondary prevention.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review

2015 ◽  
Vol 22 (1) ◽  
pp. 1-16 ◽  
Author(s):  
Roberta Agabio ◽  
Pier Paolo Pani ◽  
Antonio Preti ◽  
Gian Luigi Gessa ◽  
Flavia Franconi
Keyword(s):  
Gender Differences ◽  
Alcohol Dependence ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Female Patients ◽  
Evaluation Of Data ◽  
Different Doses

The aim of this study was to evaluate whether the number of women recruited for studies to establish the efficacy of medications approved for treatment of alcohol dependence (AD) and of alcohol withdrawal syndrome (AWS) is sufficient to reveal possible gender differences in the response to these medications and in suggesting the use of different doses in female patients. Our results show that the rates of women recruited for studies evaluating the efficacy of disulfiram (1%), benzodiazepines (3%), and anticonvulsants (13%) were too low to establish possible gender differences. The rates of women recruited for studies evaluating the efficacy of acamprosate (22%), naltrexone (23%), and nalmefene (30%) were higher and allowed evaluation of data obtained for female patients. Women receive medications for treatment of AD and/or AWS for which efficacy has been demonstrated in studies in which men were more largely represented.

Gamma-hydroxybutyrate (GHB) withdrawal syndrome: First case report in Lithuania (Kaunas addiction treatment center)

2016 ◽  
Vol 33 (S1) ◽  
pp. S302-S302 ◽  
Author(s):  
K. Jucys ◽  
A. Leleikiene ◽  
D. Jokuboonis
Keyword(s):  
Withdrawal Syndrome ◽  
Addiction Treatment ◽  
Clinical Course ◽  
Anaesthetic Agent ◽  
Epidemiological Data ◽  
Treatment Center ◽  
First Case ◽  
Gamma Hydroxybutyrate ◽  
Competing Interest ◽  
Opioid Withdrawal Syndrome

Gamma-hydroxybutyrate (GHB) is a γ-aminobutyric acid (GABA) precursor and metabolite that naturally occurs in the human body. Initially, GHB was used as an anaesthetic agent but was later also found to have anabolic, hypnotic, antidepressant, anxiolytic as well as cholesterol lowering effects. Recently though, research into GHB has been carried out primarily in assessing its effectiveness in treating alcohol and opioid withdrawal syndrome. There are no epidemiological data about GHB consumption in Lithuania, however during last decade there were observed many fatal cases of GHB users due to GHB intoxication or withdrawal abroad. In this article we will present the clinical case and problems which face the patient of 2-year daily GHB consumption. There were observed mild to moderate abstinence state presented with its clinical course and peculiarities. Whereas using GHB is becoming more popular in Lithuania, it is very important to pay attention to this substance and problems related to its usage.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sodium Valproate in the Treatment of the Alcohol Withdrawal Syndrome

1980 ◽  
Vol 14 (3) ◽  
pp. 213-215 ◽  
Author(s):  
D. G. Lambie ◽  
R. H. Johnson ◽  
M. E. Vijayasenan ◽  
E. A. Whiteside
Keyword(s):  
Alcohol Dependence ◽  
Sodium Valproate ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
The Other ◽  
Withdrawal Symptoms ◽  
Control Group ◽  
Electrolyte Replacement

The value of sodium valproate in the management of patients during withdrawal from alcohol dependence has been assessed. Alcoholic inpatients were randomly allocated to two groups — one treated with sodium valproate and the other acting as a control. All patients received multivitamins and fluid and electrolyte replacement, and some received chlormethiazole or other tranquillisers. Treatment with sodium valproate (1200 mg daily) was continued for one week. The occurence of seizures and other withdrawal symptoms (tremulousness, nausea, sweating, disorientation) were noted daily. Forty-nine episodes of withdrawal have been included in the trial — 22 in the sodium valproate group and 27 in the control group. Five patients, all in the control group, had seizures. Other withdrawal symptoms disappeared more quickly in the sodium valproate group even though fewer patients were receiving chlormethiazole.

Novel Targets Explored in Treatment of Alcohol Dependence induced Withdrawal Syndrome

2020 ◽  
Vol 19 ◽  
Author(s):  
Antra Gupta ◽  
Heena Khan ◽  
Amarjot Kaur ◽  
Thakur Gurjeet Singh
Keyword(s):  
Alcohol Dependence ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Clinical Status ◽  
Alcohol Withdrawal Syndrome ◽  
Therapeutic Interventions ◽  
Clinical Aspects ◽  
Gamma Aminobutyric Acid ◽  
Novel Targets

: Alcohol withdrawal syndrome (AWS) is characterized as termination of chronic and sustained alcohol use that leads to severe symptoms of distress or loss of daily functions when alcohol consumption is diminished or stopped. It is a debilitating manifestation of alcohol dependence and responds poorly to the available clinical therapies. Globally alcohol drinking is continuously increasing all across the world. It causes 3.3 million deaths every year (5.9% of all deaths), and 5.1% of the global burden of disease. Alcohol Withdrawal syndrome led to various changes in brain neurotransmitters sys-tem such as GABA, glutamate, non-epinephrine, serotonin. These symptoms result from imbalance in brain receptor be-tween gamma aminobutyric acid (GABA) and N methyl aspartate (NMDA) that occurs when the consumption of alcohol stops after long use. Studies from various in vivo and in vitro animal models of alcohol withdrawal have been conducted to explore new targets for treatment of alcohol withdrawal syndrome. Advancements in the elucidation of AWS mechanism have revealed a number of key targets that have been hypothesized to modulate clinical status. The present review discusses the pathophysiology, neurobiology and treatment of alcohol withdrawal syndrome and its novel targets like corticotrophin releasing factor, sigma, melanocortin-4 receptors, opioid, potassium channels, ghrelin, and endocannabinoid receptors and gut microbiota. This review discusses about various clinical and pre- clinical aspects related with alcohol dependence. The exploration of novel pharmacological targets may provide effective therapeutic interventions for the management of alcohol withdrawal syndrome.

Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention

2013 ◽  
Vol 15 (2) ◽  
pp. 245-257 ◽  
Author(s):  
Katrin Skala ◽  
Fabio Caputo ◽  
Antonio Mirijello ◽  
Gabriele Vassallo ◽  
Mariangela Antonelli ◽  
...  
Keyword(s):  
Alcohol Dependence ◽  
Alcohol Withdrawal ◽  
Relapse Prevention ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Sodium Oxybate ◽  
Alcohol Relapse

scholarly journals Sensitivity to placebo therapy in patients with alcohol dependence in postwithdrawal period

2018 ◽  
Vol 16 (4) ◽  
pp. 55-60
Author(s):  
Viktor V. Vostrikov ◽  
Petr D. Shabanov
Keyword(s):  
Placebo Group ◽  
Alcohol Dependence ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Emotional State ◽  
Alcohol Withdrawal Syndrome

40 patients with alcohol dependence in post-abstinent period was used to study the psychological peculiarities of emotional-motivational sphere during the course of placebo therapy. The placebo-reactor was 62.5%, placebo preaction – 15%, placebo-negative reactors of 22.5%. There are significant differences in the compared groups of patients. After a course of placebo-therapy all patients showed positive changes in emotional state, most pronounced in placebo-directoru. The least pronounced changes in the placebo group-negative patients (but to lessen the desire for alcohol most pronounced). The conclusion about the need for a differentiated approach to the treatment of alcohol withdrawal syndrome and postdetoxification state.

Sign in / Sign up

Export Citation Format

Share Document